Tuesday, March 1, 2005 :: New CT Laser Mammography Technology Featured at Largest EU Radiology Congress
New CT Laser Mammography Technology Featured at Largest EU Radiology Congress


Symposium on CTLM And 3D Absorption To Be Moderated by Professor Eric Milne


Fort Lauderdale, Florida, March 1st, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that the CT Laser Mammography system (CTLMâ) will be featured at the 2005 European Congress of Radiology (ECR) conference, held March 4-8, in Vienna, Austria. (Booth 338)

A key symposium entitled: “CTLM And 3D Absorption And Fluorescence Optical Molecular Imaging Of Human Breast Cancer,” moderated by Professor Eric Milne, Director of Clinical Research at IDSI, will be held Sunday, March 6. Notable symposium presentations by CTLM users include,

Contrast Enhanced Optical Imaging Of The Breast: Status And Future Prospects,
by C. Bremer, M.D., Munster, Germany.
CTLM and MR Imaging, by A. Poellinger, M.D., Berlin, Germany
CTLM and Mammography, by D. Floery M.D., Vienna, Austria
Benign Angiogenesis, by Moderator and Professor E. Milne, M.D., USA

One of the world’s largest medical congresses, the 11th annual ECR will attract approximately 13,000 participants. The 2005 Congress will highlight new trends in radiology such as whole-body imaging with MRT, PET/CT Lung Cancer Screening and Interventional radiology. “CTLM as a new imaging modality fits the format nicely,” according to IDSI VP International, Mr. Janusz Ostrowski. “Also, IDSI’s global commercialization program has recently focused on Europe where we have established seven centers-of-excellence and completed recent sales. The ECR is an important meeting to promote laser optical breast imaging and only IDSI can do it with 3D CT technologies,” continued Ostrowski.

The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, February 15, 2005 :: CT LASER MAMMOGRAPHY FEATURED AT 30TH
CT LASER MAMMOGRAPHY FEATURED AT 30TH
ARAB HEALTH EXHIBITION AND CONGRESS 2005

Fort Lauderdale, Florida, February 15, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), announced it featured the CT Laser Mammography (CTLM®) system at the 30th Arab Health Exhibition and Congress in Dubai, United Arab Emirates, Feb 12-15, 2005. Now in its 30th year, Arab Health Exhibition and Congress is the largest healthcare event in the Middle East and one of the most important. With the Middle East healthcare market valued at US$ 74 billion annually, the event has been attracting more and more exhibitors and visitors each year.
Arab Health 2005 gave companies opportunity to showcase their products and services in one of the fastest growing, and most lucrative healthcare markets in the world. A total of 1,422 exhibitors from 50 countries, including 25 national country pavilions displayed their healthcare products and services to over 30,000 visitors in 2004. This year attendance was equally robust.

According to Mr. Janusz Ostrowski, IDSI Vice President-International Sales, “I am very happy with the tremendous interest in CT Laser Optical Mammography shown at the Arab Health Conference. We are the only company to offer 3D images of the breast and we do it in a painless, radiation-free exam. As previously announced, we now have three CTLM systems in the region.”

The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Monday, February 7, 2005 :: SECOND CT LASER MAMMOGRAPHY SYSTEM SOLD IN ITALY
SECOND CT LASER MAMMOGRAPHY SYSTEM SOLD IN ITALY



Fort Lauderdale, Florida, February 7th 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that it has shipped and sold a second CTLMâ system to its distributor Biomedical International SNC, for installation at the Biomedical Mammography Center, Alba Adriatica, Teramo, Italy.

“We recently began marketing the CTLM system and these new sales demonstrate that the revolutionary laser optical breast imaging technology is gaining acceptance in Italy as a beneficial diagnostic tool”, stated G. Luciano Perazzi, President of Biomedical International.

Tim Hansen, Imaging Diagnostic Systems CEO, stated, "This is the fourth operating CTLM system in Italy and the second sale in the country. We will soon have operating CTLM systems in the university setting, general hospitals and now a mammography center. Wherever women receive conventional x-ray mammography exams the CTLM may serve a useful adjunctive service.”

The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Thursday, February 3, 2005 :: CZECH REPUBLIC SIGNS CT LASER MAMMOGRAPHY AGREEMENT
CZECH REPUBLIC SIGNS CT LASER MAMMOGRAPHY AGREEMENT

SEVENTH CLINICAL SYSTEM PLACED IN EUROPE

Fort Lauderdale, Florida, February 3, 2005—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that Charles University Hospital in Prague, Czech Republic has signed a clinical collaborative agreement to gather data to expand diagnostic applications of the proprietary CT Laser Mammography (CTLMâ) system.

“At the Department of Radiology of Charles University, Polak Family Breast Diagnostic Center in Prague, we perform thousands of diagnostic breast exams annually with the latest imaging devices. Adding this remarkable CT Laser Breast Imaging technique, which images the process of angiogenesis, will add new dimension to our clinical service," stated Professor Jan Danes, Head, Department of Radiology.

“We are delighted to have Professor Danes and the fine staff at Charles University join our clinical development efforts. This agreement marks our seventh of eight targeted European sites. Each site selected will perform a variety of studies to introduce laser optical breast imaging technology into their respective areas and promote product awareness,” commented Deborah O’Brien, IDSI Senior Vice President.

The CTLMâ system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com